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of colorectal cancer in diabetes patients:
a meta-analysis
Lei Wang1, Shuang Cai2, Zan Teng3, Xin Zhao1, Xinyue Chen1 and Xiaojuan Bai1*Abstract
Background: Recent epidemiological studies suggest that treatment with insulin may promote cancer growth. The
present systematic review and meta-analysis of published observational studies was conducted to assess the risk of
cancer during treatment with insulin.
Materials and methods: A compressive search was conducted through MEDLINE, PubMed, Web of Science,
EMBASE, and Chinese Biomedical Literature databases (CBM). Pooled relative risks (RRs) and 95% confidence
intervals (CIs) were calculated with a random-effects model.
Results: A total of four studies with one case-controls study and three cohort studies comparing the insulin therapy
and colorectal cancer susceptibility were identified. When all four studies were analyzed, the summary RRs were
1.61 (95% CI = 1.18–1.35) in a random-effects model for individuals with insulin therapy, compared with individuals
without insulin therapy, which suggests a statistically significant association between insulin use and colorectal
cancer.
Conclusions: Our findings provides the evidence that insulin therapy may contribute to the risk of colorectal
cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9339731010859509Introduction
Colorectal cancer (CRC) is a leading cause of cancer-
related morbidity and mortality in the Western world.
Obesity, Western-style diet, and lack of physical activity
are established risk factors for CRC [1]. Few epidemio-
logic studies have evaluated whether insulin treatment
is associated with risk of CRC [2-4]. Two retrospective
studies, with clinical data from the United Kingdom,
reported roughly 2-fold higher odds of CRC among type
2 DM patients who used insulin [2,4]. There was a null
association between insulin use and CRC risk in a simi-
lar retrospective study conducted with data from US
pharmacies [3]. An effect of insulin on colon carcino-
genesis is biologically plausible. In studies conducted* Correspondence: xiaojuanbai_sy@163.com
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stated.with rats, insulin administration appears to promote colon
cancer growth and to increase proliferation in colonic epi-
thelial tissue [5,6]. Whether insulin treatment increases
risk of CRC is an important question because almost all
patients with type 2 DM will eventually require insulin
treatment [7].
In line with these considerations, it has been hypothe-
sized that insulin use might influence CRC development. In
the past years, several eligible case–control or cohort stud-
ies were performed to identify the association of insulin use
with CRC risk. However, the results remain inconclusive
and inconsistent. To date, no meta-analysis has been con-
ducted to investigate the association between insulin ther-
apy and CRC susceptibility. Hence, a meta-analysis based
on a total of four independent studies was performed,
which may provide the evidence for association of insulin
therapy with CRC susceptibility.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Search strategy
We conducted a comprehensive search using key
words “DM”, “diabetes”, “CRC”, “colorectal neoplasm”,
“colon cancer”, “colon neoplasm”, “rectal cancer”, “rectal
neoplasm”, “insulin” and “insulin therapy” in the following
key electronic biomedical databases MEDLINE, PubMed,
Web of Science, EMBASE, and Chinese Biomedical
Literature databases (CBM) without date and language
restrictions, and all eligible studies were detected before
September 2013. Their reference lists were hand-searched
to find other relevant publications. Titles and available
abstracts were scanned for relevance, identifying pa-
pers requiring further consideration. Of the studies
with overlapping data published by the same investiga-
tors, only the most recent or complete study was in-
cluded in this meta-analysis.
Eligibility and exclusion criteria
To be included in the meta-analysis, a published study
had to meet the following criteria: (1) only original articles
of a quantitative assessment of the relationship of insulin
therapy and risk of colorectal cancer, (2) cohort studies,
(3) adult human population, and (4) insulin or one of insu-
lin products as the main independent variable, (5) results
expressed as relative risk (RR), (6) studies with a 95% CI
for RR, or sufficient data to calculate these numbers.
While for the exclusion criteria, we provided as follows:
(1) case–control or case-only studies, family-based studies,
case reports, editorials, and review articles (including
meta-analyses); (2) controls with other types of tumors,
and (3) studies that did not provide data that allowed cal-
culation of standard errors for effect estimates and if the
estimates were not adjusted for age and gender were ex-
cluded. Moreover, when there were multiple publications
from the same population or cohort, only data from the
most recent report were included. In studies with overlap-
ping cases/controls, the higher quality score, or the study
with more information on origin of cases/controls was in-
cluded in the meta-analysis.
Data extraction
Information was carefully extracted from all eligible
publications independently by two authors according
to the inclusion criteria listed above. Disagreement was
resolved by discussion between the two authors. The
following data were collected from each study: the first
author’s last name, year of publication, and country of
population studied, study design, number of exposed
and unexposed subjects, follow-up period, age, gender,
type of DM (type 2 or combined type 1 and type 2), risk
estimates with their corresponding confidence intervals,
and variables controlled for by matching or in the multi-
variable model, numbers of cases and controls with theinsulin therapy and CRC, respectively. For each study,
we extracted the risk estimates that reflected the great-
est degree of control for potential confounders. We did
not limit the number of patients to include a study in
our meta-analysis.
Statistical analysis
We used the crude ORs or RRs with their correspond-
ing 95% CI as the metric of choice. Based on the indi-
vidual ORs or ORs, the pooled OR was estimated.
Summary RR estimates with their corresponding 95%
CIs were derived by the method of DerSimonian and
Laird [8] using both fixed and random effects models.
The fixed effects model was used when there was no
heterogeneity of the results of studies; otherwise, the
random-effects model was used. To take into account
the possibility of heterogeneity across the studies, a stat-
istical test for heterogeneity was performed using the Q
statistic. The heterogeneity was considered significantly
when P was below 0.10. It was assessed using the I2 stat-
istic, which takes values between 0% and 100% with
higher values denoting greater degree of heterogeneity
(I2 = 0–25%: no heterogeneity; I2 = 25–50%: moderate
heterogeneity; I2 = 50–75%: large heterogeneity; I2 = 75–
100%: extreme heterogeneity) [9]. To assess sources of
heterogeneity, we conducted a meta-regression and sub-
group analyses. Publication bias was assessed by visual
inspection of funnel plot [10]. Formal statistical assess-
ment of funnel plot asymmetry was done with Egger’s
regression asymmetry test and adjusted rank correlation
test [11]. In addition, Begg’s adjusted rank correlation
test and the trim-and-fill method were used [11,12].
Sensitivity analysis was used to explore the extent to
which inferences might depend on a particular study or
group of studies. Statistical analyses were carried out
with Stata, version 12.0 (Stata Corp, College Station,
TX, USA) and Review Manager (version 5.0). P < 0.05
were considered statistically significant. All statistical
tests were two-sided.
Results
Study characteristics and meta-analyses
Through literature search and selection, a total of four
studies with one case-controls study and three cohort
studies [2,4,13,14] comparing the insulin therapy and CRC
susceptibility were identified. Chung et al. performed a
case–control study, including 100 CRC patients and 225
controls, all the subjects are of type 2 diabetes [13].
Cambell et al. listed 2,809 patients, exposed and compar-
ing group were 11,335 and 143,660 subjects, respectively.
All these subjects are also of type 2 diabetes [14]. Currie et
all listed 292 CRC patients, exposed and comparing group
were 10,067 and 52,742 subjects, respectively. All these
subjects are also of type 1 and 2 diabetes [4]. Yang et al.
Wang et al. Diagnostic Pathology 2013, 8:180 Page 3 of 4
http://www.diagnosticpathology.org/content/8/1/180listed 125 patients, exposed and comparing group were
3,160 and 21,758 subjects, respectively. All these subjects
are also of type 2 diabetes [2]. Of these four studies, one
was from Korea [13], while one were from UK [2,4], and
the other from USA [14]. When all four studies were ana-
lyzed, the summary RRs were 1.61 (95% CI = 1.18–1.35) in
a random-effects model for individuals with insulin ther-
apy, compared with individuals without insulin therapy,
which suggests a statistically significant association be-
tween insulin use and colorectal cancer.
Sensitivity analysis
In order to compare the difference and evaluate the sensi-
tivity of the meta-analysis, we conducted one-way sensitiv-
ity analysis to evaluate the stability of the meta-analysis.
The statistical significance of the results was not altered
when any single study was omitted, confirming the stabil-
ity of the results (data was not shown). Hence, results of
the sensitivity analysis suggest that the data in this meta-
analysis are relatively stable and credible after exclusion
small size of studies.
Publication bias
For publication bias assessing, Begg’s and Egger’s test were
employed. Begg’s funnel plot was performed to assess the
publication bias of the literature. The shapes of the funnel
plots did not reveal significant evidence of obvious asym-
metry. Furthermore, Egger’s test was used to provide stat-
istical evidence for funnel plot symmetry. The results still
did not suggest any evidence of publication bias.
Discussion
In this present work, one case–control study [13] and
three cohort studies [2,4,14] showed that insulin therapy
was associated with risk of CRC. To the best of our know-
ledge, it is the first systematic review that has investigated
the association of insulin use and CRC susceptibility.
Chung et al. [13] found patients who received chronic
insulin therapy had three times the risk of CRC com-
pared with patients who received no insulin (OR = 3;
95% CI = 1.1–8.9). Yang et al. [2] found chronic insulin
therapy significantly increases the risk of CRC among
type 2 DM patients (HR = 2.1; 95% CI = 1.2–3.4). Currie
et al. [4] found insulin therapy increased the risk of
CRC compared with metformin therapy (HR = 1.69,
95% CI = 1.23–2.33). Whereas, Campbell et al. [14] ob-
served insulin use was not associated with a substantially
increased risk of CRC (RR = 1.05; 95% CI = 0.82–1.36). In
our present meta-analysis, the summary RRs were 1.61
(95% CI = 1.18–1.35) in a random-effects model for indi-
viduals with insulin therapy, compared with individuals
without insulin therapy.
Similar to other systematic reviews and meta-analysis,
our study also has some limitations: (1) small sample sizeis limitation in our work, (2) publication bias may be
present, although we have used our best efforts to identify
relevant reports/articles, (3) most of the studies did not
distinguish between types 1 and 2 diabetes, (4) diabetes is
an under-diagnosed disease, and some degree of misclassi-
fication of exposure to diabetes is likely to have occurred,
and (5) meta-analysis is just a statistical test that is subject
to many methodological restrictions and is not able to
control for other relevant factors.
Some limitations listed above, there are also some ad-
vantages should be emphasized. Our results may have im-
portant clinical and public health implications. DM is a
serious and growing health problem worldwide. CRC, one
of the most common malignancies of the gastrointestinal
tract, is a significant health problem. Meta-analysis pro-
vided a popular method for combining world literatures
across studies to resolve the statistical power and discrep-
ancy problem in associate studies [15-18]. The growing
worldwide frequency of diabetes will probably increase as
a result of the insulin or insulin related products therapy,
and thus this disease may contribute to the development
of additional cases of CRC. In order to acquire a more
rational approach to CRC prevention and treatment in
diabetic patients, more evidence and mechanisms needs
to be properly obtained.
In conclusion, our analysis suggests that insulin therapy
will significantly increase the risk of colorectal cancer.
More well-designed with larger sample studies will be
needed to verify our results.
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